COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in the technology’s future implementation and uptake.

“A blockchain-based distributed ledger can provide a critical solution for streamlining product tracking and recalls, while at the same time mitigating issues such as drug shortages and counterfeiting,” said Urte Jakimaviciute, Senior Director of Market Research at GlobalData.

“However, with the current crisis, blockchain may not be a top priority for the healthcare industry and any blockchain-related investments may be put on hold.

“Companies may shift their focus to operational resilience and agility, as well as remote workforces. While risk management in supply chains is extremely important for the pharmaceutical sector, blockchain technologies are still emerging, therefore the return on investment is hard to assess.”

Blockchain implementation in pharmaceutical product supply chains is currently in early pilot stages. The Drug Supply Chain Security Act (DSCSA) was enacted in 2013 in US prompted companies such as IBM, KPMG, Merck & Co and Walmart to explore blockchain technology.

In February 2020, these companies issued a report declaring the blockchain pilot program successful in addressing the stated objectives and demonstrating compliance with the DSCSA. Nevertheless, they also highlighted a need to develop a defined industry governance framework associated with the blockchain network and standards for information exchange, such as GS1.

There are number of limitations and challenges that technology providers, industry and governments need to address in order to bring blockchain developments forward. Aside from compliance, regulations and governance challenges, issues related to security for Internet of Things (IoT) devices, access control and scalability may present additional barriers and risks.

Jakimaviciute said: “While blockchain provides an extremely appealing use case in pharmaceutical supply chains, due to the lack of ‘real world’ applications, the COVID-19 crisis may present a temporary setback for blockchain rather than encouraging growth.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Celltrion given the go-ahead for anti-COVID-19 antibody trial

Celltrion’s Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has been approved...

Related news

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...